Charles River Laboratories International 

€169.75
63
-€0.1-0.06% Hari ini

Statistik

Harga Tertinggi Hari Ini
169.75
Harga Terendah Hari Ini
169.75
52M Tinggi
-
52M Rendah
-
Volume
0
Rata-Rata Volume
-
Kap Pasar
10.21B
Rasio P/E
23.65
Hasil Dividen
-
Dividen
-

Mendatang

Pendapatan

30OctDiharapkan
Q1 2023
Q2 2023
Q3 2023
Q4 2023
Q1 2024
Q2 2024
Berikutnya
1.91
2.13
2.35
2.56
EPS yang Diharapkan
2.18761416616
EPS Aktual
T/A

Orang Juga Mengikuti

Daftar ini didasarkan pada daftar pantauan orang-orang di Stock Events yang mengikuti RV6.F. Ini bukan rekomendasi investasi.

Peserta

Daftar ini adalah analisis berdasarkan peristiwa pasar terbaru. Ini bukan rekomendasi investasi.

Peringkat Analis

219.88Rata-Rata Target Harga
Perkiraan tertinggi adalah €250.
Dari 9 peringkat dalam 6 bulan terakhir. Ini bukan rekomendasi investasi.
Beli
33%
Tahan
67%
Jual
0%

Tentang

Charles River Laboratories International, Inc. provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing). The RMS segment produces and sells rodents, and purpose-bred rats and mice for use by researchers. This segment also provides a range of services to assist its clients in supporting the use of research models in research and screening pre-clinical drug candidates, including research models, genetically engineered models and services, insourcing solutions, and research animal diagnostic services. The DSA segment offers early and in vivo discovery services for the identification and validation of novel targets, chemical compounds, and antibodies through delivery of preclinical drug and therapeutic candidates ready for safety assessment; and safety assessment services, such as toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics services. The Manufacturing segment provides in vitro methods for conventional and rapid quality control testing of sterile and non-sterile pharmaceuticals and consumer products. This segment also offers specialized testing of biologics that are outsourced by pharmaceutical and biotechnology companies. It also provides contract vivarium operation services to biopharmaceutical clients. The company was founded in 1947 and is headquartered in Wilmington, Massachusetts.
Show more...
CEO
Mr. James C. Foster J.D.
Karyawan
20400
Negara
US
ISIN
US1598641074
WKN
000939391

Daftar